In case you missed it, POLITICO recently covered FUJIFILM Diosynth Biotechnologies’ efforts to educate Washington on its position as a premier partner for domestic manufacturing, particularly as lawmakers work to avert drug shortages.

“FUJIFILM Holdings America wants lawmakers to know that it does more than make cameras,” Megan reports. “The company is establishing a Washington presence, hiring lobbyists to highlight its biopharmaceutical work as Congress considers ways to help avert drug shortages and increase domestic manufacturing of medicines.”

Company subsidiary FUJIFILM Diosynth Biotechnologies is a partner to some major drug-makers – known as a contract development and manufacturing organization (CDMO) – for biologics, vaccines, advanced therapies and oncolytic viruses, a therapy used to treat cancer.

“The plan is to introduce the company to lawmakers and public health officials to its role in the domestic production of pharmaceuticals as the U. S. continues to grapple with supply-chain issues in the wake of the pandemic,” said Joe Metzger, vice president of corporate communications, FUJIFILM Holdings America Corporation. “Supply-chain issues have led to shortages in products such as cancer drugs and asthma medication.”

Learn more about FUJIFILM Diosynth Biotechnologies.